Nomegestrol
| Clinical data | |
|---|---|
| Other names | 19-Normegestrol; 6-Methyl-17α-hydroxy-δ6-19-norprogesterone; 17α-Hydroxy-6-methyl-19-norpregna-4,6-diene-3,20-dione |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H28O3 |
| Molar mass | 328.452 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Nomegestrol (INN), also known as 19-normegestrol, is a steroidal progestin which was patented in 1975 but was never marketed. It is the parent compound of nomegestrol acetate, which is marketed as a progestin.
Nomegestrol shows relatively low affinity for the progesterone receptor, only about 4% of that of progesterone and about 1.6% of that of nomegestrol acetate in one assay.